Observational analysis reported higher DNA methylation levels in survivors of hematologic malignancies, suggesting potential epigenetic alterations post-therapy.
Key Points
Methylation profiles in cancer survivors differ significantly from age-matched controls, indicating epigenetic changes after treatment.
Survivors of Hodgkin's Lymphoma, Acute Promyelocytic Leukemia, and Acute Myeloid Leukemia show 2.34%, 6.93%, and 10.68% higher DNA methylation, respectively.
Principal Component Analyses reveal clear separation of differentially methylated sites among cancer survivor cohorts.
Findings underscore ongoing risk of epigenetic changes in hematopoietic progenitors, calling for further research and treatment considerations.